Blueprint Medicines (BPMC) Tops Q1 EPS by 50c

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($2.15), $0.50 better than the analyst estimate of ($2.65). Revenue for the quarter came in at $63.3 million versus the consensus estimate of $41.85 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• OceanaGold to acquire Ausgold in a deal valued at A$776M
• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight